Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines

European Journal of Cancer, Journal Year: 2025, Volume and Issue: 220, P. 115369 - 115369

Published: March 22, 2025

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has high cure rate when managed appropriately. Advances in the understanding biological characteristics, coupled improvements diagnostic tools therapeutic approaches, have significantly improved patient outcomes recent years. In this article, we present set pragmatic guidelines developed by Lymphoma Study Association (LYSA) for management PMBCL. These address key aspects diagnosis, staging, response evaluation, treatment, integrating latest evidence from clinical trials, expert consensus, real-world practice. The aim to provide clinicians clear, practical framework optimize care patients PMBCL, ensuring that best available translated into

Language: Английский

---

Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse/refractory lymphoma: A 20-year Singapore experience

Annals of the Academy of Medicine Singapore, Journal Year: 2025, Volume and Issue: 54(1), P. 5 - 16

Published: Jan. 23, 2025

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative option for relapse/refractory (R/R) lymphomas that have failed autologous or high-risk in the upfront setting. We conducted retrospective analysis on consecutive lymphoma patients who underwent allo-HSCT over 20-year period (2003- 2022) at Singapore General Hospital and National University Singapore. A total of 121 were included study. Median age was 41 years. Diagnoses include Hodgkin (HL, 15%), B-cell non- (B-NHL, 34%), T-cell non-Hodgkin (T-NHL, 31%) natural killer (NKTL, 20%). Moreover, 27% had prior auto-haematopoietic transplanta-tion (auto-HSCT), 84% received reduced intensity conditioning (RIC). Donor types matched sibling donor (45%), unrelated (29%), haploidentical (19%) cord blood (CB, 7%). After median follow-up 56 months, estimated 4-year progression-free survival (PFS) overall (OS) all 38% 45%, respectively. Non-relapse mortality (NRM) 15% day 100 24% 1 year. On univariate analysis, complete remission status transplant RIC confers superior OS. multivariate HL associated with OS compared to NHL, whereas significantly inferior donor. Long-term durability observed relapsed/ refractory lymphomas. This real-world data serves as valuable historical benchmark future studies Asia Pacific region.

Language: Английский

---

Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report

Hematology Reports, Journal Year: 2025, Volume and Issue: 17(3), P. 22 - 22

Published: April 23, 2025

Background and Clinical Significance: Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation, often associated with prolonged immunosuppression. Diffuse large B-cell lymphoma (DLBCL) the most common subtype. Managing PTLD requires balance between reducing immunosuppression preventing graft rejection. Case Presentation: A 41-year-old female kidney transplant recipient developed eight years post-transplant, presenting right submandibular mass. Biopsy confirmed CD20-positive DLBCL. Initial treatment involved rituximab monotherapy, which failed to prevent disease progression. The patient underwent six cycles R-CHOP chemotherapy, achieving complete metabolic remission. Relapse occurred twice, progression in cervical nodes tonsils. Salvage therapies, including polatuzumab vedotin rituximab, achieved During subsequent relapse, loncastuximab tesirine induced resolution. Compromised renal function limited options second was delayed, risk recurrence. Conclusions: This case underscores challenges managing recipients, especially relapsed/refractory cases. Single-agent insufficient, but combination chemotherapy novel agents like were effective. Balancing oncologic control preservation remains critical. highlights need for individualized approaches therapies while addressing complexities preservation.

Language: Английский

---

Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study

Journal of Cancer Research and Therapeutics, Journal Year: 2025, Volume and Issue: 21(2), P. 447 - 456

Published: May 1, 2025

ABSTRACT Background and Purpose: The ability of autologous hematopoietic stem cell transplantation (ASCT) to improve the benefit patients with high-risk diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) following induction chemotherapy is controversial. This multicenter real-world study aimed explore efficacy safety rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) regimen followed by consolidated ASCT therapy in newly diagnosed DLBCL. Methods: From June 2018 2021, clinical data DLBCL reached CR after receiving R-CHOP from ten diagnosis treatment centers were analyzed. Patients included R-CHOP+ASCT (with therapy, n = 60) (follow-up without groups. two groups was compared difference analysis, Results: Until 2024, median follow-up times for 44 (37.25–56) 43.5 (38–52) months, respectively. Survivors up at least 36 months. In group, 3-year disease-free survival (DFS) overall (OS) rates 89.7% 96.7% those group 63.9% 85.9%, DFS rate significantly higher than that (89.7% vs 63.9%, P 0.001); no significant found OS between (96.7% 0.113). 5-year 73.6% 77.6% 56.5% 81.1%, (73.6% 56.5%, 0.009), whereas (77.6% 0.246). Cox multifactorial discontinuous bone marrow invasion, dual expression poor prognostic factors affect [hazard ratio (HR), 5.710; 95% confidence interval (CI), 2.241–14.548, < 0.001; HR, 4.324; CI, 1.890–9.893, 2.565; 1.145–5.747, 0.022, respectively] a factor (HR, 3.486; 1.300–9.344, 0.013). Grade IV myelosuppression developed other common grade 3 or 4 treatment-related adverse events infection fever. Conclusion: For DLBCL, can increase status regimen, controllable.

Language: Английский

---

Navigating CAR-T cell therapy long-term complications

Nature Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

Language: Английский

---

Clonal hematopoiesis of indeterminate potential: the root cause of, and fertile ground for, hematological malignancies

Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---